PDS Biotechnology Funding Round

9/8/2026

Venture Equity

$22,550,000

Undisclosed

The Company intends to use the net proceeds from the private placement to repay outstanding indebtedness and for working capital and general corporate purposes, including the continued development of its clinical programs, research and development, and general and administrative expenses.

Private & Independent

Biopharmaceutical

303A College Road East
Princeton, NJ 08540
USA

PDS Biotech was established with the goal of harnessing the power of T cells to address some of the most devastating illnesses of our time. While many companies have tried to leverage the body's own immune system to induce a powerful T cell response, most have been unsuccessful in overcoming the tumor's ability to protect itself against the immune system and also inducing the right type and quantity of potent tumor-infiltrating T cells to execute a targeted attack. Our proprietary targeted technologies are designed to deliver IL-12 into the tumor's inner environment to suppress the tumor's ability to protect against T cells while simultaneously generating a potent targeted T cell attack on the cancer.